Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMSCs for Epilepsy During DBS Surgery
NCT06280092Phase 1Terminated
- Sponsor
- Mayo Clinic
- Start
- Dec 2024
- Primary completion
- Sep 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CSCC_ASC in epilepsy, sponsored by Mayo Clinic. Primary endpoints: Incidence of Adverse Events at 12 months and Radiographic effects related to the study agent at 12 months. Started Dec 2024; status: terminated.
02
Drugs
CSCC_ASC
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT06280092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06280092.